1.

Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma--their prognostic significance.

Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M, Ohashi K.

Pathol Int. 2012 Dec;62(12):792-801. doi: 10.1111/pin.12019.

PMID:
23252868
2.

Expression of cancer stem cell markers and their correlation with pathogenesis in vascular tumors.

Lan J, Huang B, Liu R, Ju X, Zhou Y, Jiang J, Liang W, Shen Y, Li F, Pang L.

Int J Clin Exp Pathol. 2015 Oct 1;8(10):12621-33. eCollection 2015.

3.

Cancer Stem Cell Markers in Eyelid Sebaceous Gland Carcinoma: High Expression of ALDH1, CD133, and ABCG2 Correlates With Poor Prognosis.

Kim N, Choung HK, Lee MJ, Khwarg SI, Kim JE.

Invest Ophthalmol Vis Sci. 2015 Feb 24;56(3):1813-9. doi: 10.1167/iovs.14-15547.

PMID:
25711631
4.

Prognostic value of CD133 expression in stage I lung adenocarcinomas.

Woo T, Okudela K, Mitsui H, Yazawa T, Ogawa N, Tajiri M, Yamamoto T, Rino Y, Kitamura H, Masuda M.

Int J Clin Exp Pathol. 2010 Dec 4;4(1):32-42.

5.

Prognostic Significance of CD44v6, CD133, CD166, and ALDH1 Expression in Small Intestinal Adenocarcinoma.

Eom DW, Hong SM, Kim G, Bae YK, Jang KT, Yu E.

Appl Immunohistochem Mol Morphol. 2015 Nov-Dec;23(10):682-8. doi: 10.1097/PAI.0000000000000140.

PMID:
25710579
6.

Differential Expression of Cancer Stem Cell Markers ALDH1 and CD133 in Various Lung Cancer Subtypes.

Roudi R, Korourian A, Shariftabrizi A, Madjd Z.

Cancer Invest. 2015;33(7):294-302. doi: 10.3109/07357907.2015.1034869. Epub 2015 Jun 5.

PMID:
26046383
7.

Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma.

Chen S, Hou JH, Feng XY, Zhang XS, Zhou ZW, Yun JP, Chen YB, Cai MY.

J Surg Oncol. 2013 Jun;107(8):799-806. doi: 10.1002/jso.23337. Epub 2013 Apr 22.

PMID:
23609373
8.

Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer.

Wakamatsu Y, Sakamoto N, Oo HZ, Naito Y, Uraoka N, Anami K, Sentani K, Oue N, Yasui W.

Pathol Int. 2012 Feb;62(2):112-9. doi: 10.1111/j.1440-1827.2011.02760.x. Epub 2011 Nov 30.

PMID:
22243781
9.

Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer.

Horst D, Kriegl L, Engel J, Kirchner T, Jung A.

Cancer Invest. 2009 Oct;27(8):844-50. doi: 10.1080/07357900902744502.

PMID:
19626493
10.

CD133 and nuclear beta-catenin: the marker combination to detect high risk cases of low stage colorectal cancer.

Horst D, Kriegl L, Engel J, Jung A, Kirchner T.

Eur J Cancer. 2009 Jul;45(11):2034-40. doi: 10.1016/j.ejca.2009.04.004. Epub 2009 May 4.

PMID:
19403300
11.

Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.

Bi Y, Meng Y, Wu H, Cui Q, Luo Y, Xue X.

J Surg Oncol. 2016 Feb;113(2):144-51. doi: 10.1002/jso.24124. Epub 2016 Jan 12.

PMID:
26799258
12.

High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.

Cortes-Dericks L, Galetta D, Spaggiari L, Schmid RA, Karoubi G.

Eur J Cardiothorac Surg. 2012 Jun;41(6):e173-81. doi: 10.1093/ejcts/ezs170. Epub 2012 Apr 23.

PMID:
22529186
13.

Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.

Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y, Muraoka T, Tanaka N, Ueno T, Asano H, Tsukuda K, Yamane M, Oto T, Kiura K, Miyoshi S.

Lung Cancer. 2012 Jul;77(1):162-7. doi: 10.1016/j.lungcan.2012.02.006. Epub 2012 Mar 3.

14.

Clinical significances and prognostic value of cancer stem-like cells markers and vasculogenic mimicry in renal cell carcinoma.

Zhang Y, Sun B, Zhao X, Liu Z, Wang X, Yao X, Dong X, Chi J.

J Surg Oncol. 2013 Nov;108(6):414-9. doi: 10.1002/jso.23402. Epub 2013 Aug 29.

PMID:
23996537
15.

The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.

Kapucuoğlu N, Bozkurt KK, Başpınar Ş, Koçer M, Eroğlu HE, Akdeniz R, Akçil M.

Pathol Res Pract. 2015 Oct;211(10):740-7. doi: 10.1016/j.prp.2015.05.011. Epub 2015 Jun 1.

PMID:
26298632
16.

Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization.

Sterlacci W, Savic S, Fiegl M, Obermann E, Tzankov A.

J Thorac Oncol. 2014 Jan;9(1):41-9. doi: 10.1097/JTO.0000000000000021.

17.

The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer.

Alamgeer M, Ganju V, Szczepny A, Russell PA, Prodanovic Z, Kumar B, Wainer Z, Brown T, Schneider-Kolsky M, Conron M, Wright G, Watkins DN.

Thorax. 2013 Dec;68(12):1095-104. doi: 10.1136/thoraxjnl-2012-203021. Epub 2013 Jul 22.

18.

AC133 expression associated with poor prognosis in stage II colorectal cancer.

Ying X, Wu J, Meng X, Zuo Y, Xia Q, Chen J, Feng Y, Liu R, Li L, Huang W.

Med Oncol. 2013 Mar;30(1):356. doi: 10.1007/s12032-012-0356-z. Epub 2013 Jan 16.

PMID:
23322518
19.

Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma.

Xi HQ, Zhao P.

J Clin Pathol. 2011 Jun;64(6):498-503. doi: 10.1136/jcp.2010.087213. Epub 2011 Mar 17.

PMID:
21415057
20.

Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy.

Mizukami T, Kamachi H, Mitsuhashi T, Tsuruga Y, Hatanaka Y, Kamiyama T, Matsuno Y, Taketomi A.

BMC Cancer. 2014 Sep 21;14:687. doi: 10.1186/1471-2407-14-687.

Supplemental Content

Loading ...
Support Center